Bomedemstat

Generic Name
Bomedemstat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H34FN7O2
CAS Number
1990504-34-1
Unique Ingredient Identifier
Y2T4ALDEAT
Associated Conditions
-
Associated Therapies
-

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-11-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT06596668
Locations
🇺🇸

Celerion, Inc. ( Site 0001), Tempe, Arizona, United States

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

First Posted Date
2024-06-13
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT06456346
Locations
🇯🇵

Fujita Health University ( Site 0613), Toyoake, Aichi, Japan

🇯🇵

Ehime University Hospital ( Site 0612), Toon, Ehime, Japan

🇯🇵

Hokkaido University Hospital ( Site 0601), Sapporo, Hokkaido, Japan

and more 58 locations

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

First Posted Date
2024-04-08
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
400
Registration Number
NCT06351631
Locations
🇺🇸

UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania, United States

🇮🇹

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo ( Site 2703), Alessandria, Italy

🇺🇸

University of Michigan ( Site 6000), Ann Arbor, Michigan, United States

and more 12 locations

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

First Posted Date
2023-10-12
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT06079879
Locations
🇨🇳

Anhui Provincial Hospital ( Site 3513), Hefei, Anhui, China

🇨🇳

Peking University Third Hospital-Hematology ( Site 3502), Beijing, Beijing, China

🇨🇳

The Second Affiliated Hospital Of Fujian Medical University ( Site 3525), Quanzhou, Fujian, China

and more 130 locations

Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2022-10-28
Last Posted Date
2024-12-17
Lead Sponsor
Terrence J Bradley, MD
Target Recruit Count
18
Registration Number
NCT05597306
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-10-06
Last Posted Date
2023-05-23
Lead Sponsor
The University of Hong Kong
Target Recruit Count
40
Registration Number
NCT05569538
Locations
🇭🇰

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-09-28
Last Posted Date
2024-11-26
Lead Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Target Recruit Count
20
Registration Number
NCT05558696
Locations
🇺🇸

BRCR Global ( Site 0120), Plantation, Florida, United States

🇺🇸

Hematology Oncology of the North Shore ( Site 0104), Skokie, Illinois, United States

🇺🇸

Ohio State University Comprehensive Cancer Center ( Site 0103), Columbus, Ohio, United States

and more 14 locations

Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-02-04
Last Posted Date
2024-03-22
Lead Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Target Recruit Count
80
Registration Number
NCT05223920
Locations
🇦🇺

Gold Coast Hospital and Health Service, Southport, Queensland, Australia

🇬🇧

Guy's and Saint Thomas' NHS Foundation Trus, London, United Kingdom

🇺🇸

University of Miami Leonard M. Miller, Miami, Florida, United States

and more 16 locations

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

First Posted Date
2022-01-14
Last Posted Date
2024-05-06
Lead Sponsor
University of Washington
Target Recruit Count
3
Registration Number
NCT05191797
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-02-05
Last Posted Date
2024-04-02
Lead Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Target Recruit Count
73
Registration Number
NCT04254978
Locations
🇳🇿

Middlemore Hospital, Auckland, New Zealand

🇩🇪

Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), Essen, Germany

🇬🇧

Guys and St Thomas Hospital, London, United Kingdom

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath